# Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

> **NCT00389207** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 576 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** nevirapine bid
- **DRUG:** nevirapine qd
- **DRUG:** atazanavir

## Key facts

- **NCT ID:** NCT00389207
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2011-02
- **Final completion:** —
- **Target enrollment:** 576 (ACTUAL)
- **Last updated:** 2014-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389207, "Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00389207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*